Listen Now

Deven McGraw, lead for Data Stewardship and Data Sharing at Invitae, joins Laura to discuss how government and industry can best secure your right to access your own health data while keeping it secure from unwanted exposures. Deven's broad range of experience makes her the person to answer those burning questions about how to keep our data safe - and accessible.

Today’s podcast features Adam Rutherford, a geneticist trained at University College London who has spent much of his career as a science communicator: as an editor at Nature, as a radio and television commentator for the BBC, and as the author of such books with delightful titles, including "Creation: the Origin of Life/The Future of Life and A Brief History of Everyone Who Ever Lived" and "How to Argue With a Racist".

In a field full of amazing people, no one --- no one -- is more remarkable than Sharon Terry. And this is despite (or perhaps because of) the fact that she is not, technically, in the field at all: Sharon Terry is, as her bio describes her, “just a mom with a master’s degree in theology.” Sharon’s personal story of a journey from the worst form of heartbreak and disempowerment – the discovery that both of her young children had a rare genetic disease with a bad prognosis – to become a role model for parent activists everywhere.

Noura Abul-Husn got her MD and PhD from Mt Sinai in NYC, where she later served as the first clinical director of the Institute for Genomic Health and Chief of Genomic Medicine. Today, she is Vice President for Genomic Health at 23andMe. She joins us here on the Beagle today to discuss the state of translational efforts in genomic medicine and look at some of the barriers to the integration of genetics into routine clinical care.

Pharmacogenetics testing: where are we today? Kristine Ashcraft, CEO, and founder of YouScript, a translational PGX start-up that Invitae recently acquired, joins us on the Beagle to discuss why it has been so hard to get the ball rolling on PGX testing. Kristine, who was called one of the 25 leading voices in precision medicine by BIS Medicine in 2019, lays out a roadmap to the integration of PGX testing into routine clinical care.

The dismantling of the right to abortion established under Roe v Wade has left many clinicians angry, uncertain, and in dire need of legal advice. If that describes you – speak to a lawyer! Don’t get your legal advice from a podcast, you silly goose. But first: you might want to listen to this conversation with Stanford’s Michelle Mello, a law and health policy professor.

A conversation with Dan Navon, associate professor of sociology at the University of California, San Diego, and the author of Mobilizing Mutations: Human Genetics in the Age of Patient Advocacy. Dan’s book encourages us to pay attention to the subtle way in which defining conditions according to their underlying genetics affects the patient experience, from shaping identity to creating a sense of solidarity within disease communities. Plus (spoiler) Dan will explain why he calls genetic counselors the ‘secret heroes’ of his research.

Allison Kurian is Director of the Stanford Women’s Clinical Cancer Genetics Program, with a practice that centers on women at high risk of breast and gynecologic cancers. Trained in internal medicine, oncology, and epidemiology, Allison has embraced genetics (a fourth specialty!) as a tool for early detection and risk stratification. Ten years after ACLU v Myriad changed the landscape of genetic testing overnight, how far have we come, and where are we headed next?

What if, someday, your doctor could order a single test able to screen for over 50 types of cancer? What if, someday, you had an effective screening option to offer patients identified with cancer susceptibility syndromes? What if, someday, we had a way to catch killers like lung, pancreatic and ovarian cancer early, when treatment was still an option? What if that day were today?

Ten years ago, prenatal testing was revolutionized by the introduction of non-invasive testing, which improved the positive predictive value of testing while reanimating concerns that have dogged reproductive genetics from the get-go: what should we test for and who should decide? Now, start-up Luna Genetics has announced its arrival, bringing to market the first non-invasive test that will look at intact cells from the fetus (well, the fetal placenta). Will Luna upend the prenatal testing market once again? NIPT took a hit with a critical front-page article in the NY Times last week.

Today on The Beagle, one of the rock stars of the genetic counseling field, Jehannine Austin, Professor of Medical Genetics at the University of British Columbia. Jehannine has pioneered the field of psychiatric genetic counseling and, more broadly, they have worked energetically for decades to make psychiatric genetic counseling – and all genetic counseling -- an evidence-based discipline.

Increasingly, algorithms and computing power are combining to turn us into both the sources and the subjects of big data. Professor Anya Prince from the University of Iowa College of Law, an expert in genetics and the law, joins us to explore the twin threats of genetic discrimination and loss of privacy in an age of SO MUCH genetic data.

22Q11 Deletion Syndrome – the most common version of a rare thing, affecting close to 1 in 1000 births – is no picnic for genetic counselors. Presentation is complex and unpredictable and can include structural, developmental, and behavioral manifestations.

Hannah Llorin is a reproductive genetic counselor at Brigham and Women’s Hospital in Boston, and Kim Zayhowski is a cancer genetic counselor at Boston Medical Center and a faculty member at the Boston University Genetic Counseling Program.

Today the Beagle welcomes Amy McGuire, Professor of Biomedical Ethics and Director of the Center for Medical Ethics and Health Policy at Baylor College of Medicine. Amy, a nationally-recognized expert in the legal and ethical issues associated with genomic medicine, joins Laura to discuss BabySeq and the high-risk, high-reward prospect of making genome sequencing of newborns routine.

Kathryn Paige Harden is a professor of psychology at the University of Texas, where she leads the Developmental Behavior Lab and co-directs the Texas twin project.

Colleen Caleshu, Senior Director of Research at GeneMatters, received the Jane Engleberg Memorial Foundation Fellowship in 2019 for a randomized controlled trial of meditation to improve genetic counselor professional well-being. She received the best abstract award at the 2021 NSGC Annual Conference for part of this work. Colleen is a Ph.D. candidate at Leiden University and a genetic counselor who specializes in cardio genetics and kindness.

Today, Laura speaks with Barbara Harrison, Assistant Professor at Howard University (and 2020 NSGC Natalie Weissberger Paul National Achievement Award winner) and Katie Stoll, executive director of Genetic Support Foundation, about the new guidelines from ACMG on expanded carrier screening: how these changes move the field forward, and how they fall short.

A cardiologist and Professor of Medicine at the University of Pennsylvania Perelman School of Medicine, Kiran Musunuru is a clinician and a researcher whose important work has moved the ball forward on gene therapy. As co-founder and scientific advisor to Verve Therapeutics, Kiran has a special perspective – an insider’s view of the business, from someone who is both an academic (MD, PhD, MPH) and a humanist at heart.

The legal landscape for abortion is changing rapidly, and in ways that will inevitably affect genetic counseling practice in many states. Joining Laura to discuss the new laws and the role that NSGC can play – if the organization decides that protecting reproductive rights is a priority for its membership-- is Jordan Brown, assistant Director at the genetic counseling program at the Ohio State University, vice chair of the NSGC Public Policy Committee, and a member of the newly formed NSGC Task Force looking at the challenges to reproductive rights.